Systematic evaluation of plasma phospholipids for reliable and precise determination of dronedarone and desbutyldronedarone by LC-MS/MS.
The objective of the present work was to minimize or eliminate the matrix effect due to plasma phospholipids as observed during sample preparation for accurate determination of dronedarone and its active metabolite, desbutyldronedarone by LC-ESI-MS/MS. The extraction recovery and matrix factors ranged from 93.27 to 95.14% and 0.99 to 1.02, respectively, for both the analytes. A linear concentration range of 0.10 to 150 ng/ml was established for both the analytes. The analytes were efficiently resolved (R(s) 2.37) on Kromasil(®) (AkzoNobel, Bohus, Sweden) C18 column within 3.0 min. The assay reproducibility was determined by reanalysis of 72 incurred samples with % change within ± 10%. The optimized solid-phase extraction provided cleaner extracts with reduced matrix effect from plasma phospholipids compared with protein precipitation and liquid-liquid extraction.